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Background: Vitiligo is a chronic depigmenting skin disorder which affects around 0.5-1% of the world’s population.
The outcome measures used most commonly in trials to judge treatment success focus on repigmentation.
Patient-reported outcome measures of treatment success are rarely used, although recommendations have been made
for their inclusion in vitiligo trials. This study aimed to evaluate the face validity of a new patient-reported outcome
measure of treatment response, for use in future trials and clinical practice.
Method: An online survey to gather initial views on what constitutes treatment success for people with vitiligo or their
parents/carers, followed by online discussion groups with patients to reach consensus on what constitutes treatment
success for individuals with vitiligo, and how this can be assessed in the context of trials. Participants were recruited
from an existing database of vitiligo patients and through posts on the social network sites Facebook and Twitter.
Results: A total of 202 survey responses were received, of which 37 were excluded and 165 analysed. Three main
themes emerged as important in assessing treatment response: a) the match between vitiligo and normal skin (how
well it blends in); b) how noticeable the vitiligo is and c) a reduction in the size of the white patches. The majority of
respondents said they would consider 80% or more repigmentation to be a worthwhile treatment response after
9 months of treatment. Three online discussion groups involving 12 participants led to consensus that treatment
success is best measured by asking patients how noticeable their vitiligo is after treatment. This was judged to
be best answered using a 5-point Likert scale, on which a score of 4 or 5 represents treatment success.
Conclusions: This study represents the first step in developing a patient reported measure of treatment success
in vitiligo trials. Further work is now needed to assess its construct validity and responsiveness to change.
Keywords: Vitiligo, Outcome measure, Patient-reported outcome, Randomised controlled trialBackground
Vitiligo is a chronic depigmenting skin disease charac-
terised by loss of skin colour in patches [1]. It affects
people of all ages, ethnic groups and skin types [2,3] and
around 0.5%-1% of the world’s population [1,2] although
estimates are higher in countries and cultures where the
stigma of the skin disease may be higher [1].
There is no cure for vitiligo but there are numerous
treatment options. These include topical and oral prepa-
rations, light therapy, surgical procedures, psychological* Correspondence: kim.thomas@nottingham.ac.uk
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unless otherwise stated.and complementary therapies [1]. The only licensed
treatment for vitiligo in the UK is cosmetic camou-
flage [3], although many other treatments are used in
clinical practice.
Physical symptoms in vitiligo are usually mild, but the
unpredictable nature of the disease and its tendency to
progress in the majority of cases can be psychologically
and cosmetically overwhelming [1,2,4]. Living with viti-
ligo can be a continuous struggle, with the psychological
characteristics of each individual determining their abil-
ity to adjust to and cope with disfigurement [5].
Although clinical studies have assessed many treat-
ments for vitiligo, the heterogeneity of these studies makes
comparison of the effectiveness of treatments – alone ord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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systematic review of interventions for vitiligo published in
2010 [1] and other reviews have highlighted problems such
as variance in design and a lack of standardised outcome
measures and scales used in clinical trials [1,2,6,7]. There is
a pressing need to develop core outcome measures, so that
effectiveness of treatments can be compared and combined
more easily across trials 2].
It is important that outcomes used in trials are rele-
vant to patients as well as clinicians [2]. Repigmentation
is the most frequently used outcome measure and is typic-
ally captured using either clinical assessments or through
digital images [2]. Vitiligo results in patches of depigmen-
ted skin, so intuitively it would seem to be a simple matter
of recording treatment success or failure based on changes
in the amount of repigmented skin. However, repigmenta-
tion of vitiligo can often be uneven, resulting in a poor cos-
metic result from a patient’s perspective.
Despite recommendations for the inclusion of patients’
views when evaluating interventions [1,6], patient-reported
outcomes have not been commonly used in trial to date
[2], and validated tools are lacking.
The aim of the study was to develop and provide prelim-
inary data on the face validity of a patient-reported out-
come measure of the acceptability of treatment response.
Specific objectives were:
 To conduct patient surveys and online discussion
groups to establish the most appropriate form of
wording and scale to use.
 To ensure that the wording of the question
assessing satisfaction with treatment response is
relevant to, and easily understood by, vitiligo
patients (face validity).
 To establish what represents clinically worthwhile
treatment response from a patient’s perspective.
In addition to improving our understanding of what
constitutes a successful treatment response from a pa-
tient perspective, it is anticipated that the resulting out-
come measure will be useful for use in future vitiligo
trials and clinical practice. The results will also be used
to inform an ongoing international initiative to establish
a core outcome set for use in vitiligo trials [8].
Methods
This project was conducted in two stages. First, an on-
line survey was used to identify which aspects of treat-
ment response are most important to patients.
The online survey was followed by three separate on-
line discussion groups, in which the results of the survey
were explored with patients, and consensus was reached
regarding the most appropriate form of wording for the
proposed patient-reported outcome measure.The project was approved by the University of
Nottingham’s Medical School Research Ethics committee
(Ethics Reference No. LTg15082013 SoM Dermatol).
Online survey
Participants
Participants were recruited from an existing mailing list
held at the Centre of Evidence-Based Dermatology at
the University of Nottingham. This list consisted of
individuals who had participated in a previous Vitiligo
Priority Setting Partnership [7] and those who had con-
tacted us expressing interest in being involved in vitiligo
research. In addition, participants were recruited through
the UK Vitiligo Society Facebook Page, and details of the
survey were ‘tweeted’ under the UK Dermatology Clinical
Trials Network Twitter feed. Participants in the survey
included both those who had sought treatment for their
vitiligo and those who had not, and included parents/
guardians of children with vitiligo as well as those with
vitiligo themselves. We did not include clinicians and
healthcare professionals who had participated in the pre-
vious Priority Setting Partnership. Efforts were made to
ensure broad representation across all age and ethnic
groups. Although recruitment was targeted largely at
participants in the UK, there were no exclusions based
on country of residence and details of nationality were
recorded.
Survey distribution
The survey, which took approximately 5minutes to
complete was created using Survey Monkey software [9]
and consisted of 14 questions. No incentives were of-
fered for participation. Prior to distribution, we piloted it
by asking a group of clinicians, researchers and members
of the Centre of Evidence-Based Dermatology (CEBD)
Patient Panel to review the survey and comment on the
relevance of the survey content and how easy it was to
understand and complete.
Details of the survey and information sheets were
emailed to 188 potential participants from an existing
mailing list held at the CEBD that included patients who
had previously expressed an interest in finding out more
about vitiligo research. The survey was open from 29th
July 2013 until the 19th August 2013. Two reminders
were emailed to all on the mailing list, and additional
posts were placed on the Vitiligo Society’s Facebook page
and the UK Dermatology Clinical Trials Network Twitter
feed in order to broaden recruitment. Completion of more
than 1 survey question implied consent to participate.
Data collection included demographic details; the ex-
tent of the vitiligo and previous treatments used; opin-
ions on what a ‘cosmetically acceptable response’ to
treatment meant to the participant and whether they
felt it was the same as ‘satisfaction with the result’. A
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response were also presented, from which participants
chose the most meaningful to them (see Results section).
Participants were also asked to look at a series of im-
ages featuring a young boy with dark skin with a vitiligi-
nous lesion. Using image manipulation software (Adobe®
Photoshop® CS2, Adobe Systems Incorporated; San Jose,
California, USA) the lesion was gradually reduced in the
sequential images to simulate repigmentation at differ-
ent percentages. Participants were asked to indicate the
degree of repigmentation that they considered worth-
while after 9 months of treatment, followed by the mini-
mum level of repigmentation they would be prepared to
accept.
Online discussion groups
Participants
Survey participants who indicated interest in further in-
volvement in research were invited to participate in an
online discussion groups. All participants received a £10
amazon e-voucher.
Invitations were sent by email, with an information
sheet attached. In total, 57 initial invitations were sent.
Reminder emails and further invitations were sent if ne-
cessary, to ensure that 6–8 people were confirmed for
each of the three discussion groups [9]. To aid par-
ticipation, two groups were held in the evening. We
used online discussion groups to make it easier for
participants to join the discussion (rather than having
to travel) and to make it easier for them to talk about
more personal aspects of their experience with vitiligo
(which might have been more difficult if they had attended
in person).
To ensure familiarity with the concepts involved and
the context in which the patient assessment of treatment
response would be placed, confirmed participants were
sent reading material on clinical research methods and
primary outcome measures (see Additional file 1). Par-
ticipants were also advised to read information on viti-
ligo from the NHS Choices web pages [10] and to watch
a short video explaining clinical trials from the Medical
Research Council via YouTube [11].
Hosting the online discussion groups
Online discussion groups were used in favour of face-
to-face focus group discussions in order to facilitate
engagement with a broad range of participants from
throughout the UK [12-14].
The online discussion groups were hosted in a private
chat room based within the Vitiligo Society’s web pages.
All participants followed an email link, registered for the
group and, once approved by the moderator (ST), were
given access to the chat room for the time of their online
discussion. Prior to the groups taking place, participantswere sent information about the objectives of the groups,
and about consent to participate. Participants gave consent
at time of registration and were encouraged to use an alias
if they wished to remain anonymous.
Each group lasted for approximately 90minutes, to allow
adequate time for discussion whilst avoiding participant fa-
tigue. Participants were able to type text and send emoti-
cons as in a standard chat room. Groups were facilitated
by two to three members of the research team.
The discussion groups were semi-structured; a list
of prompts was prepared in advance and these were
inserted into the discussion thread at relevant time
points. This ensured similarity between the questions
asked of each group. Page links were created for images
and inserted into the discussion thread at relevant times
during the discussion to allow participants to view im-
ages of vitiligo before and after treatment and a selection
of measurement scales.
Examples of prompts used in online discussion
groups:
Discussion prompts were used to direct participants’
attention to relevant points. Here are examples of prompts
used under various themes covered by the online discus-
sion groups:
Prompt number and details
Theme: Most important concepts when assessing treat-
ment success
The survey results showed that the three main areas of
importance to people with regards to judging treatment
success were (in order of frequency):
1. Colour match between their vitiligo and normal skin
i.e. how well it blends in
2. How noticeable the vitiligo is
3. A reduction in the size of the white patches.
Which of these do you think is the most important if
we are trying to capture a measure of treatment success?
Theme: Wording of questions about how noticeable
vitiligo is
Let's try some example questions that ask about how
noticeable your vitiligo is. These questions can be used
at the end of a trial to ask people about how successful
their treatment is. What do people think about these
possible questions? Does the wording seem right?
Q1 How noticeable do you feel your vitiligo is,
compared with the start of treatment?
Q2 How successful do you feel the treatment has been,
in terms of how noticeable the vitiligo is?
Q3 How satisfied are you with how noticeable the
vitiligo is?
Q4 Compared to before treatment, how noticeable is
your vitiligo now?
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ment response for whole body versus individual lesions
If some areas of vitiligo respond well to treatment and
some do not, do you think that this question is useful to
measure how noticeable the vitiligo is on all body sites
affected? Or do you think that the question is only use-
ful for assessing individual patches of vitiligo?
Adequate time was allowed after insertion of each
prompt to allow participants to respond and discuss
with each other freely. The facilitators guided discussion
with the aim of trying to achieve consensus, and sum-
marised the discussion findings at various intervals to
check that all participants were in agreement.
At the end of the discussion group, a copy of the en-
tire discussion thread was downloaded and saved.
Sample size and participant selection
The sample size for this study was dictated by the time
and resources available. However, we aimed to include at
least 100 participants in the survey (assuming a confi-
dence interval of 95%, and an accuracy rate or +/− 10%)
and 18 – 20 participants in the discussion groups, in
order to gather a broad selection of views.
For the discussion groups, purposive sampling was
used to ensure diversity in terms of ethnicity and age
within the groups. Using SPSS 21 Software, potential
participants who had responded to the online survey
were split into three groups – parents/carers of those
with vitiligo (n = 13), people with vitiligo aged 17–45
(n = 45) and those aged 46 and above (n = 76). We tried
to take participants’ ages into consideration when form-
ing the discussion groups given the potentially greater fa-
miliarity with technology and “text speak” in younger
participants [13]. Invitations were sent to all parents/
carers, plus a random selection from other age groups.
All potential participants from non-white ethnic back-
grounds were invited, as well as a random selection of
those from white backgrounds. This was to enable dis-
cussion of treatment for vitiligo in the context of differ-
ent skin types.
Statistical analysis
Survey results were analysed using SPSS Statistics 21
software. Results were presented descriptively. Responses
to open questions were analysed thematically by a re-
searcher (ST) and checked by a second researcher (JB)
for agreement. This allowed for comparison between
themes emerging from open and closed questions to be
made, as well as allowing for ranking of themes by
popularity overall for use in the discussion groups.
The main objective of the discussion groups was to
seek consensus regarding the most appropriate wording
of the question to ask people about the response of
vitiligo to treatment. Whilst more formal methods ofconsensus development (e.g. Delphi and Nominal Group
Technique) are the focus of much academic consideration,
informal consensus groups such as those employed here
are commonly employed in health care settings [15]. To
counter some of those criticisms that informal mecha-
nisms for consensus reaching lack ‘control’, ‘focus’ and ‘sci-
entific credibility’ [15] here data is handled and analysed
systematically following an adapted version of Template
Analysis [16,17]. Template analysis utilises a hierarchical
model to organise text in order to aid interpretation. In
this case each point of consensus was taken as a higher-
level organising code within which to summarise and con-
sider the group discussion. So for each point of agreement
the discussion which led toward this was considered
and coded to reflect those factors which contributed
towards the consensus and those which were a barrier.
This process was completed for each discussion group
with a final template constructed to include all state-
ments where agreement spanned the different groups.
This mode of analysis provides greater depth in under-
standing consensus, both mapping where agreement oc-
curred and charting the process and factors which
generated it. Two researchers independently checked the
copy of each discussion group thread to ensure that all
relevant points had been adequately identified and ex-
tracted with any discrepancies discussed with a third re-
searcher. Consensus points are summarised below, with
examples of key comments made by participants. The
qualitative aspect of this study adhered to the RATS
guidelines for reporting qualitative research modified for
BioMed Central [18].
Results
Participants
In total, 202 survey responses were received. Of these,
165 (82%) were included in analyses, and of these, 154
(76%) were fully completed surveys (Figure 1).
Responses were excluded for the following reasons:
 If the survey had been completed from the same
Internet Protocol (IP) address more than once:
○ The first completely filled survey was included,
and the rest excluded.
○ If multiple surveys were completed fully, only
the first was included.
 The same two rules applied for duplicate email
addresses given
 If the survey had not been completed past question 1,
it was excluded.
The only exception to these exclusion criteria was where
email addresses and demographic responses indicated that
two different individuals had responded from the same IP
address, so both sets of responses were included.
Figure 1 Participant flow diagram. Flow diagram to show participant numbers lost and included throughout the study process.
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summarised in Table 1.
The majority of participants were aged between 31
and 65 years of age and had had vitiligo for more than
10 years. One hundred and thirty three (80.6%) of those
completing the survey were from white ethnic back-
grounds, and 135 (81.8%) were from the UK.
Results of survey
Question 1: “When thinking about repigmentation of
vitiligo after treatment, what does a ‘cosmetically
acceptable result’ mean to you?”
There were 143 responses to this open question. Mul-
tiple themes per response were allowed, yielding a total
of 237 items of information coded from the 143 re-
sponses. The three most common themes related to the
concept of the skin returning to normal and the vitiligo
patches being less visible or noticeable. Reduction in the
size of the lesion was ranked 4th and was mentioned in
just 12.2% of responses. The main themes to emerge are
summarised in Table 2.
Six responses were not relevant to the question, such
as “I have given up on treatment after various unsuc-
cessful attempts”. Four respondents (1.7%) stated specif-
ically that a ‘cosmetically acceptable result’ was not
meaningful to them and not an encouraging phrase.
Question 2: “The list below gives some possible words or
phrases used to describe treatment results in vitiligo.
Please tell us the words/phrases that best reflect how
you would judge whether or not a vitiligo treatment
has worked (please tick up to THREE options)”This question received 157 responses. The most popu-
lar words/phrases are summarised in Table 3. Eighteen
responses (4.3%) were given under the category ‘Other’,
and most were not relevant to treatment response, such
as “Never had treatment”.
Question 3: “When thinking about the repigmentation
of vitiligo after treatment, do you think that ‘cosmetic
acceptability of result’ and ‘satisfaction with the result’
mean the same thing?”
In total, 159 responses were given for this question,
with 88 (55.3%) answering ‘No’, 46 (28.9%) answering
‘Yes’ and 25 (15.7%) ‘Not sure’.
An open comment box allowed respondents to give
further details, which suggested that participants felt that
‘cosmetic acceptability’ was a medical view or that of
someone else and that ‘satisfaction with the result’ was a
more personal and patient-led view. An example re-
sponse was “The second statement suggests that the
person is happy with the result whereas the first state-
ment sounds more medical…”. In addition, negative
views about the term ‘cosmetic acceptability’ were
given, such as “rather vague”, “impersonal” and “implies
vitiligo only affects skin”.
Question 4: “Please give us any other suggestions on
the questions we should ask people about the result of
vitiligo treatment.”
The main theme that emerged was asking questions
regarding psychological factors, (36 responses; 34.6%)
such as individual feelings, confidence, and comfort in
wearing fewer clothes. The next emerging themes were
Table 1 Demographic/other characteristics of survey
respondents
Characteristic Online survey Online discussion
groups
N = 165 N = 12
Responses completed on behalf of – n (%)
Themselves 149 (90.3) 12 (100)
Other 14 (8.5)
0 (0)Child with vitiligo 13(92.9)
Spouse with vitiligo 1 (7.1)
Themselves and other(s) 2 (1.2) 0 (0)
Unknown 0 (0) 0 (0)
Age – n (%)
<5 years 1 (0.6) 0 (0)
5-16 years 10 (6.1) 1 (8.3)
17-30 years 17 (10.3) 2 (16.7)
31-45 years 43 (26) 3 (25)
46-65 years 55 (33.3) 3 (25)
> 65years 29 (17.6) 3 (25)
Unknown 10 (6.1) 0 (0)
Ethnicity- n (%)
White British 117 (70.9) 9 (75)
White Irish 1 (0.6) 0 (0)
Other White Background 15 (9.1) 0 (0)
Any Other Mixed Background 1 (0.6) 0 (0)
Indian/British Indian 9 (5.5) 1 (8.3)
Pakistani/British Pakistani 1 (0.6) 0 (0)
Bangladeshi/British Bangladeshi 2 (1.2) 1 (8.3)
Caribbean/British Caribbean 1 (0.6) 1 (8.3)
African/British African 1 (0.6) 0 (0)
Other 7 (4.2) 0 (0)
Unknown 10 (6.1) 0 (0)
Country of residence – n (%)
UK 135 (81.8) 11 (91.7)
USA 12 (7.3) 1 (8.3)
Europe (excluding UK) 3 (1.8) 0 (0)
Australia 1 (0.6) 0 (0)
Asia 1 (0.6) 0 (0)
Dual – UK and Other 2 (1.2) 0 (0)
Unknown 11 (6.7) 0 (0)
Duration of Diagnosis- n (%)
6-12 months 3 (1.9) 0 (0)
1-2 years 3 (1.9) 0 (0)
2-5 years 12 (7.7) 2 (16.7)
5-10 years 26 (16.8) 1 (8.3)
> 10 years 111 (71.6) 9 (75)
Table 1 Demographic/other characteristics of survey
respondents (Continued)
Percentage of skin affected (estimate) - n (%)
0-10% 37 (23.3) 1 (8.3)
10-25% 49 (30.8) 4 (33.3)
25-50% 33 (20.8) 5 (41.7)
50-80% 24 (15.1) 2 (16.7)
>80% 16 (10.1) 0 (0)
Unknown 6 (3.6) 0 (0)
Area (s) of skin affected – n (%) NB: More than one response could be given
Face/Neck 129 (78.2) 10 (83.3)
Body 110 (66.7) 7 (58.3)
Arms 113 (68.5) 8 (66.7)
Legs 109 (66.1) 8 (66.7)
Hands 127 (77) 10 (83.3)
Feet 113 (68.5) 9 (75)
I’d rather not say 2 (1.2) 0 (0)
Other (responses included:
under arms, genitalia and hair)
35 (21.2) 2 (16.7)
Treatments used previously – n (%) NB: More than one response could be given
No treatment 57 (34.5) 2 (16.7)
Topical corticosteroid 41 (24.8) 3 (25)
Protopic (Tacrolimus) 46 (27.9) 6 (50)
Elidel (Pimecrolimus) 6 (3.6) 0 (0)
Vitamin D derived cream or
ointment (e.g. calcipotriol)
5 (3) 2 (16.7)
UVB 33 (20) 5 (41.7)
PUVA 20 (12.1) 2 (16.7)
Not Sure 1 (0.6) 0 (0)
Other (Responses included diet
changes and alternative therapies)
28 (17) 3 (25)
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the duration of the improvement (14 responses; 13.5%).
Other results are summarised in Table 4.
Question 5: “After 9 months of vitiligo treatment, which
of the pictures below shows a level of treatment response
that you feel would be worthwhile to you? Please choose
the letter associated with the chosen image.”
The 158 responses are summarised in Table 5. Almost
80% of participants said that they would consider at least
an 80% improvement to be a worthwhile result after
9 months of treatment (equating to images G H and I).
Question 6: “After 9 months of vitiligo treatment, which of
the pictures below represents the MINIMUM treatment
response that you would be prepared to accept?”
Table 2 ‘When thinking about repigmentation of vitiligo
after treatment, what does a “cosmetically acceptable
result” mean to you?’ (Themes in descending order of
popularity)
Theme Number of responses Percent
Blends well with skin 45 19%
Less noticeable 35 14.8%
Skin back to normal 31 13.1%
Reduction in white patches 29 12.2%
Confident/Comfortable 25 10.5%
Repigment visible sites 19 8%
Any Improvement 17 7.2%
Mostly repigmented 14 5.9%
Cosmetics 9 3.8%
Unaffected by tanning 5 2.1%
Means nothing 4 1.7%
Lasting repigmentation 3 1.3%
Completely depigmented 1 0.4%
Table 4 Themes emerging from “other suggested
questions”
Theme Number of Responses Percent
Psychological 36 34.6%
Treatment details 19 18.3%
Improvement duration 14 13.5%
Was the treatment worth the results 8 7.7%
Adverse effects 6 5.8%
Satisfaction 6 5.8%
Back to normal 4 3.8%
Has colour returned 3 2.9%
Reduction in white patches 3 2.9%
Sun protection 2 1.9%
Would they do it again 2 1.9%
Make it simple 1 1%
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to Question 5, when asked to identify the MINIMUM
acceptable treatment response, the results were heavily
skewed towards high levels of repigmentation. Sixty four
percent of participants wanted to see at least a 70% im-
provement after 9 months of treatment (images F, G, H
and I), although improvement of as little as 50% was also
considered worthwhile for some.
Key messages to be explored in discussion groups
The survey revealed some key messages, which were
taken forward to the online discussion groups for further
exploration.Table 3 Popularity of Words/Phrases to describe treatment
results for vitiligo
Words/Phrases Number of
votes
Percent
Good colour match between treated vitiligo
patches and normal skin
72 17%
Skin is back to normal 66 15.6%
Feel better about appearance of skin 58 13.7%
Reduction in area of skin affected by vitiligo 48 11.3%
Even pattern of repigmentation 43 10.2%
Cosmetically acceptable result 26 6.1%
Satisfied with result 23 5.4%
Worth continuing with treatment 21 5%
Other 18 4.3%
Worthwhile result 17 4%
Result of treatment is acceptable 9 2.1%The first of these was that there were three main areas
of importance to people when judging treatment suc-
cess, namely: colour match between their vitiligo and
normal skin, i.e. how well it blends in; how noticeable
the vitiligo is; and a reduction in the size of the white
patches.
Another key message for further exploration was
that the majority of respondents said they would con-
sider 80% or more repigmentation to be worthwhile
treatment response after 9months and that the mini-
mum they would be prepared to accept would be 70%
repigmentation.
Results of discussion groups
Three online discussion groups were held, involving a total
of 12 participants (n = 4; n = 3 and n = 5 respectively). Par-
ticipants ranged in age from 16 to over 65 years old, andTable 5 Worthwhile treatment response and minimum
level of response acceptable for after 9 months
Treatment response
image (Approximate%
repigmentation)
Worthwhile treatment
response
Minimum treatment
response acceptable
Number of votes
(cumulative %)
Number of votes
(cumulative %)
A (20) 2 (1.3) 8 (5.1)
B (30) 0 (1.3) 8 (10.2)
C (40) 3 (3.2) 7 (14.7)
D (50) 7 (7.6) 17 (25.6)
E (60) 8 (12.1) 16 (35.9)
F (70) 12 (19.8) 26 (52.6)
G (80) 18 (31.6) 43 (80.2)
H (95) 57 (77.7) 22 (94.3)
I (100) 51(100) 9 (100)
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An additional four participants were registered to join
the groups, but did not participate because they had
technical difficulties in accessing the chat room, or
were unavailable at the last minute. Due to participant
availability, we were not able to run separate discussion
groups for participants of different age groups, as we
had planned. However, this did not seem to have an ad-
verse effect on any participants’ ability to contribute to
discussions. A total of 50 pages (approximately 16,000
words) of text were obtained from the three groups
and analysed as described above.
Summary of areas of consensus
All three groups achieved consensus both within and
between the individual discussion groups in several
areas.
Points for which there was consensus across the groups
included:
i. The most important concept when asking about
success of treatment response is “how noticeable the
vitiligo is after treatment”.
ii. A scale with five response options (both words and
numbers) is the best scale to use when answering
the question
Question: Compared to before treatment, how
noticeable is the vitiligo now?
a. More noticeable (1)
b. As noticeable (2)
c. Slightly less noticeable (3)
d. A lot less noticeable (4)
e. No longer noticeable (5)
iii. A score of 4 or 5 on the above five-point scale would
represent a successful treatment response
iv. The question should only be used to assess
individual vitiligo lesions, rather than all areas
affected by vitiligo
These areas of consensus are discussed in more detail
below.
Most important concept: How noticeable vitiligo is
after treatment
In response to the question regarding the most im-
portant concept when judging treatment success, all
three groups were unanimous that the most important
concept was how ‘noticeable’ the vitiligo is after treat-
ment. Although some participants initially felt that
other concepts were important, after further discussion
with other participants, consensus was soon reached,
with minimal input from the facilitators. Moreover,
several participants commented that the ‘noticeability’
of the vitiligo was a useful ‘catch-all’ phrase whichcovered elements of the other two concepts (colour
match/blending and a decrease in size of the lesions).
For example:
‘Of the three you have written, I think 1 and 3 are
covered by 2’
‘I would say, most noticeable first, as 1 and 3
determine this’
Participants in all groups acknowledged that for people
with paler skin tones, ‘noticeability’ may be less of an
issue than for people with darker skin:
Participant: I am lucky in that I have very fair
skin so my condition is not that easy to
notice……… but I imagine it is a big issue if it
can be seen.
Facilitator: Do you think that if your vitiligo was in
visible areas, that how noticeable it was would be the
most important to you?
Participant: Yes
Having established that the ‘noticeability’ of the vitiligo
was the most important concept, participants then de-
cided on the best wording of the question to ask trial
participants in order to establish the ‘noticeability’.
Prompts used for this discussion are shown in the
‘examples of prompts used in online discussion groups’
subsection.
There was agreement that asking about “satisfaction”
alongside the notion of “noticeability” was confusing
for patients, as the two terms have contradictory
implications.
‘Because noticeable to me, denotes it is noticeable-
which is a negative and yet I am being asked how sat-
isfied I am-which is a bit confusing’
There was rapid development of consensus in the first
two groups that Q4 (‘Compared to before treatment,
how noticeable is your vitiligo now?’) was the most ap-
propriate and easy to understand, and the third group
agreed with this:
‘Love it- uncomplicated and to the point’
What scale to use when answering the question
When groups were asked about the best scale with
which to measure responses to the question, a prefer-
ence was expressed for a linear scale, as opposed to a scale
made up of images such as pictograms or emoticons.
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contain a reasonable number of choices:
‘I think it’s sometimes more difficult to make a
judgement when there are fewer parameters’
Although the first group expressed a provisional pref-
erence for a linear scale with 10 divisions, time was lim-
ited for discussion of this point and so the discussion
was developed further in groups 2 and 3. The subsequent
groups felt that a 5-point scale with adjectival markers
was best.
Having agreed on the question ‘Compared to before
treatment, how noticeable is your vitiligo now?’ in group
1, further discussion with the participants in groups 2
and 3 showed support for the response options shown in
the left-hand column of Table 6. The final wording of
two responses was amended slightly after the discussion
groups had been completed (so that all responses con-
sistently included the word ‘noticeable’). The amended
wording, shown in the right-hand column of Table 6,
was circulated amongst all participants and there was
unanimous support for it.
What score on the scale constitutes treatment ‘success?’
The groups were unanimous that a ‘successful’ treatment
would need to score at least a ‘4’ on this scale (a lot less
noticeable [4] or no longer noticeable [5]).
In particular, participants expressed a preference for
having both numbers and words on the scale, and for
the option of ticking a box to give an answer.
Participants in all groups agreed that the question and
scale were suitable when assessing vitiligo lesions that
have partially repigmented but which, due to hyperpig-
mentation or uneven repigmentation, are actually more
noticeable after treatment. Here is a summary of a dis-
cussion when participants in one group were shown
some ‘before and after’ images that included hyperpig-
mentation (Figure 2 for images):
Participant 1: That is interesting. There is a reduction in
vitiligo area but the patchiness makes it look more
obvious. In spite of the partial repigmentation, I would
answer 1.Table 6 Wording of response options
Wording agreed during
discussion groups
Amended wording, approved after
discussion group by participants
Worse than before (1) More noticeable (1)
About the same (2) As noticeable (2)
Slightly less noticeable (3) Slightly less noticeable (3)
A lot less noticeable (4) A lot less noticeable (4)
Hardly noticeable (5) No longer noticeable (5)Participant 2: On balance I think I would say 2, because
the area near to the eye has responded well but the chin
seems more noticeable now that it is not such a large
block
Participant 3: To me it is more blotchy so 1
Facilitator: So if this was your vitiligo, would you say
that treatment was successful or unsuccessful?
Participant 2: Unsuccessful I think
Participant 1: Partly successful, but if I had to opt for
successful or unsuccessful, I would go for unsuccessful
as it has made the vitiligo more obvious.
Participant 3: Unsuccessful.
Use of the question to refer to individual treated vitiligo
lesions or all affected areas of vitiligo
In the final discussion group, participants were asked to
comment specifically on whether the question could be
used to ask about all areas affected by vitiligo or whether
it was best used to assess specific patches (see ‘examples
of prompts used in online discussion groups’ subsection
for prompts). Participants were unanimous that the ques-
tion should be specific to target areas, and that this was
particularly important for visible sites.
Use of the question with children and their parents/carers
The third group was also asked about the suitability of
the question if the trial participant was a child, and a
proxy response from a parent or carer was required:
‘I feel that parents could answer for their child as they
would be fully aware of the child’s feelings’
‘I think the questions would be suitable for children,
although their responses might be a bit more
optimistic than adults’
‘For a child, I think noticeability will be determined by
their peers - a parent may or may not have good
insight into this’
Discussion
Summary of main findings
This work has provided valuable insight into how patients
with vitiligo evaluate treatment success and has laid the
foundation for creating a validated patient-rated outcome
measure for use in future trials of vitiligo treatments.
Although the concept of a ‘cosmetically acceptable result’
had previously been identified as an important measure of
treatment success amongst people with vitiligo [2], our
Figure 2 A set of ‘before’ and ‘after’ images showing hyperpigmentation used in the online discussion groups. A set of ‘before’ and
‘after’ images showing hyperpigmentation used in the online discussion groups. This set of images consent was gained from the individual
seen in Figure 2 for use of their images in research publications as well as was obtained from images held at the Centre of Evidence Based
Dermatology of before and after treatment. Full future studies.
Tour et al. BMC Dermatology 2014, 14:10 Page 10 of 12
http://www.biomedcentral.com/1471-5945/14/10initial survey work showed that this term was rather un-
helpful to patients, who felt that it was vague, impersonal
and rather ‘medical’; or it implied that vitiligo was just
something to be covered up (using cosmetic camouflage).
There was good agreement between the open and
closed responses to survey questions. Common themes
including ‘blends well with skin’, ‘less noticeable’ and
‘reduction in white patches’, were mentioned most fre-
quently in response to an open question. While the most
popular phrases in response to a more closed question
were: ‘good colour match’, ‘reduction in area of skin af-
fected’ and ‘even pattern of repigmentation’.
‘Feel better about appearance of skin’ was another
popular theme, and although this is a highly important
concept, we did not pursue it further in the discussion
groups because psychological response to treatment was
beyond the remit of this study. Specific validated scales
to assess the impact of vitiligo on psychological well-
being have been described elsewhere [19,20] as have
quality of life scales regarding physical appearance and
cosmetic products [21].
Another main theme to emerge from the survey re-
sults was that many respondents equated a cosmetic-
ally acceptable result with ‘skin is back to normal’.
Although this is of course the ideal result for people
with vitiligo, the likelihood of vitiliginous skin fully
returning to normal after treatment is low. In addition,
responses to a question about the skin being ‘back to
normal’ would be in a binary ‘Yes/No’ form and would
not allow for a scale of more gradual increments,which is more likely to be useful when measuring the
partial repigmentation expected after treatment. ‘Skin
back to normal’ would also be covered by the top rat-
ing on any scale used to judge treatment success. For
these reasons, we decided not to pursue this theme
further during the discussion groups, focusing instead
on the other three key themes that had emerged
(colour match between their vitiligo and normal skin;
how noticeable the vitiligo is; and a reduction in the
size of the white patches).
Responses to survey questions about the minimum
level of repigmentation considered to be worthwhile
after a 9-month period of treatment showed that people
with vitiligo generally hope for very high degrees of
repigmentation; nearly 80% of respondents said they
would consider 80% or more repigmentation to be worth-
while and 64% said that the minimum they would be
prepared to accept would be 70% or more repigmen-
tation. This was helpful in guiding our understanding
of what patients might consider to be a clinically
meaningful treatment response and corresponds with
the quartile of >75% repigmentation being taken to
represent treatment success in many previous vitiligo
trials [2].
The online discussion groups used in the second stage
of this work were very successful and popular amongst
the participants. Due to the widespread availability of
internet access and increasing familiarity with online
means of communication, online discussion groups are
emerging as a useful medium for conducting health
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use of electronic communication to support group deci-
sion making and consensus making [22].
It was striking that the members of the online discus-
sion groups quickly reached consensus in a number of
areas. The first area of consensus was that the ‘notice-
ability’ of vitiligo was the most important concept when
assessing treatment success, and that the ‘noticeability’
of vitiligo is a useful ‘catch-all’ concept that reflects the
other two main concepts to emerge from the survey
(colour match/blending and a decrease in size of the
lesions).
Consensus was also reached rapidly regarding the use of
a 5-point scale of responses, including words and numbers,
when answering the question: ‘Compared to before treat-
ment, how noticeable is the vitiligo now?’ Participants were
happy that this scale was suitable for assessing lesions
with different percentages and patterns of repigmentation,
and there was strong consensus that a score of 4 or 5 on
the scale equated with treatment success. Participants
also agreed unanimously that if individual vitiligo lesions
are treated, the noticeability of the lesions should be
assessed individually, as opposed to assessing notice-
ability of vitiligo as a global measure for all affected areas
of skin.
Conclusions
Strengths and limitations of the study
Limitations of this research work include the fact that
the participants involved in the survey and discussion
groups were almost entirely based in the UK. It is pos-
sible that the views of people with vitiligo in other
countries may be quite different from those in the UK,
and this may limit the external validity of the patient-
rated measure. Another limitation was the absence of
parents/carers of children with vitiligo from the dis-
cussion groups. We tried hard to recruit such individ-
uals to the groups, by offering to host the groups at
times that would be convenient for them, but none of
the parents/carers who had participated in the survey
were willing, or able, to join the discussion groups.
We did, however, obtain positive feedback from parents/
carers about the outcome measure after the discussion
groups had taken place. Because it is not possible to
know the characteristics of those who chose not to re-
spond to the survey, it is possible that a degree of bias
may have arisen due to a particular cohort of participants
choosing to respond.
Given the potentially disproportionate impact of viti-
ligo on people with darker skin types, it was possibly
disappointing that only 4.2% of study participants were
from black and ethnic groups. However, this figure is
representative of the mix of ethnicities in the UK
population. For example, 85.8% of survey participantswere white, and the Office of National Statistics esti-
mates that 87.9% of the population are white; 7.7% of
participants were Indian, Pakistani or other of Asian
ethnicity, compared to the ONS estimate of 5.8% of
the UK population [7].
In this work, we did not explore participants’ views on
the impact of vitiligo on their quality of life. There is
already and extensive literature on this subject, and
there are validated vitiligo-specific quality of life scales
available for assessing this [19]. Once fully validated, the
outcome measure we are developing can be used in par-
allel with vitiligo-specific quality of life scales, to assess
both the visual and psychological aspects of treatment
‘success’ from the patient’s perspective.
Qualitative research such as this can be prone to biases if
carried out by one particular group (e.g. clinicians). Our
group included two clinicians, a psychology student, a
non-clinical Professor of applied dermatology research,
and two qualitative researchers. We believe this is a
suitable mix to avoid some of the potential for bias in
the design and interpretation of the study.
Implications for research
This work has demonstrated for the first time that per-
centage repigmentation may not be the best measure of
vitiligo treatment success from a patient’s perspective.
Instead, how noticeable the vitiligo patches are is a key
concept for patients. Greater awareness of patients’ per-
spectives in judging treatment response in future clinical
trials is essential. Additional work is now required to
validate this measure further; in particular with respect
to construct validity. We will ensure that these findings
are incorporated into future international discussions re-
garding the most appropriate core outcome measure for
inclusion in future vitiligo trials.
Additional file
Additional file 1: Background reading material on clinical research
methods and primary outcome measures given to participants
before participation in online discussion groups.
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